Trial Profile

A Phase 1 study to evaluate the PK, dosing and tolerability of LYT-100 in healthy older adults healthy older adults aged 60-79, an age group consistent with that of the IPF patient population to inform the clinical development of LYT-100 across multiple indications

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deupirfenidone (Primary) ; Pirfenidone
Indications COVID-19 respiratory infection; Idiopathic pulmonary fibrosis; Lymphoedema
Focus Adverse reactions; Pharmacokinetics
Sponsors PureTech Health

05 Sep 2022 According to a PureTech Health media release, this trial supports the dosages that were selected for the Phase 2 trial of LYT-100, which began in June 2022.
05 Sep 2022 According to a PureTech Health media release, results from this study presented at the European Respiratory Society (ERS) International Congress
05 Sep 2022 Results published in the PureTech Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com